## A combined ELONA-(RT)qPCR approach for characterizing DNA and RNA aptamers selected against PCBP-2

Miguel Moreno<sup>1</sup>, María Fernández-Algar<sup>1</sup>, Javier Fernández-Chamorro<sup>2</sup>, Jorge Ramajo<sup>2</sup>, Encarnación Martínez-Salas<sup>2</sup>, Carlos Briones<sup>1,3,\*</sup>

- <sup>1</sup> Laboratory of Molecular Evolution. Centro de Astrobiología (CSIC-INTA), Torrejón de Ardoz, Madrid, Spain.
- <sup>2</sup> Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.
- <sup>3</sup>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
- \*Correspondence and requests for materials should be addressed to C.B. (e-mail: cbriones@cab.inta-csic.es)

## SUPPLEMENTARY TABLES

**Supplementary Table S1**. Sequences of the 26 individual (75 to 76 nt-long) ssDNA aptamers selected after 10 rounds of SELEX process using PCBP-2 as the target molecule. Aptamers marked with an asterisk showed binding capacity to PCBP-2 higher than that of the last SELEX round population and M1-40 starting library (Figure 3), and were further characterized by ELONA-qPCR (Figure 5 and Supplementary Figure S5) as well as colorimetric ELONA (Supplementary Figures S9). Aptamers 05DS10-02 and 05DS10-03 showed identical sequence. Nucleotides highlighted in bold correspond to the 40 nt-long selected sequence within each aptamer.

Name	DNA aptamer sequence
05DS10-01*	GCGGATCCAGACTGGTGTGCACAGCACATGCATTACTGCGGTAATCCGTGTCCTTTGTGCCCTAAAGACAAGCTTC
05DS10-02*	GCGGATCCAGACTGGTGT <b>ACTGGGCTAGTTGCCTCTGCAGATTAGATGACAGTG</b> GCCCTAAAGACAAGCTTC
05DS10-03	GCGGATCCAGACTGGTGT <b>ACTGGGCTAGTTGCCTCTGCAGATTAGATGACAGTG</b> GCCCTAAAGACAAGCTTC
05DS10-04	GCGGATCCAGACTGGTGTGGCACTCTTGCTACCGGGACTCTCCCACTTTCTCACGGGGCCCTAAAGACAAGCTTC
05DS10-05*	GCGGATCCAGACTGGTGT <b>ACCTGTTAGCAAGAGTTTATTATGTAAAGATATCCGTTGG</b> GCCCTAAAGACAAGCTTC
05DS10-06	GCGGATCCAGACTGGTGT <b>AGTTCTCCTCTTTAAGATGCTTTATACGGCGTCTTATTAT</b> GCCCTAAAGACAAGCTTC
05DS10-07	GCGGATCCAGACTGGTGT <b>TGTGGCTACTATCCCTTGGTTATAAGTCTCATGCTCGCTG</b> GCCCTAAAGACAAGCTTC
05DS10-08	GCGGATCCAGACTGGTGTACCTGATAGGCTGATCTTAGGTGAGGAGGTTACCTGTCGTGCCCTAAAGACAAGCTTC
05DS10-09	GCGGATCCAGACTGGTGTGTGTGTGTGTGGGTCTATTATTACAAAGTACCCCCCGTATGCCCTAAAGACAAGCTTC
05DS10-10	GCGGATCCAGACTGGTGT <b>TAACCGGATCGCGCCCTCCTCGCTATCCCCCTCGGTGGT</b> GCCCTAAAGACAAGCTTC
05DS10-11	GCGGATCCAGACTGGTGT <b>CCTCAAACAATCCCGATTCAAACAGCCTCTTCCTTAGTGT</b> GCCCTAAAGACAAGCTTC
05DS10-12*	GCGGATCCAGACTGGTGTGCAGGTATGCCGGATCATGTCGTGAAAGTATCCATTTCTCGCCCTAAAGACAAGCTTC
05DS10-13	GCGGATCCAGACTGGTGTGGCTCACAGAACAGCCTTGAGTTTTATTTCCCTGCCGTTTGCCCTAAAGACAAGCTTC
05DS10-14	GCGGATCCAGACTGGTGT <b>ATCCCTACGCATCGTGTCCTCGACAGACTATGGATCAGTC</b> GCCCTAAAGACAAGCTTC
05DS10-15	GCGGATCCAGACTGGTGTGGCGCTGCGCTGCTGGTGGTCCCTCTTTGCCTATTGTTGTGCCCTAAAGACAAGCTTC
05DS10-16	GCGGATCCAGACTGGTGTGGGGGGGGGGGGTTTCTACCTTAATTCCGTTCCTGGTAACTCCGCCCTAAAGACAAGCTTC
05DS10-17	GCGGATCCAGACTGGTGT <b>TTCGGTGGGGTGGTTTAGTATCTGATTGTCATGTTGTT</b> GCCCTAAAGACAAGCTTC
05DS10-18*	GCGGATCCAGACTGGTGT <b>CCTATCTATAATTTTGCAGTCCACGTTTCTCTTGTGTGTG</b>
05DS10-19	GCGGATCCAGACTGGTGTGGCTTTGCTGTATACAAAGTGCTTTGGTCTTTCGGATTGTGCCCTAAAGACAAGCTTC
05DS10-20	GCGGATCCAGACTGGTGTGGCGCCCGTTTTCGCTGCTCACTTCGCAGAAGGTCATCCGGCCCTAAAGACAAGCTTC
05DS10-21*	GCGGATCCAGACTGGTGT <b>GGAGGTTAGCCGAAACACGTATACGCGTATTTATCCTCGG</b> GCCCTAAAGACAAGCTTC
05DS10-22*	GCGGATCCAGACTGGTGT <b>CAATGGTACTCTTCATTGTAGTCGCTTTGTTTATTAGCCG</b> GCCCTAAAGACAAGCTTC
05DS10-23	GCGGATCCAGACTGGTGT <b>TGCAGCATCGCGTCACGCGTCTACATTGTTCGTCTCACC</b> GCCCTAAAGACAAGCTTC
05DS10-24	GCGGATCCAGACTGGTGTGCCATTACCATGGATCTGTCACCCGCTCTCTCCCCGGGGCGCCCTAAAGACAAGCTTC
05DS10-25	GCGGATCCAGACTGGTGT <b>GGATACGTAACTTGCTATTGATTTGCAATTGTTGATTAT</b> GCCCTAAAGACAAGCTTC
05DS10-26*	GCGGATCCAGACTGGTGTGGGGAATGTTGTTTATGTATTTGTTCTGAGCTCTACCTTTGCCCTAAAGACAAGCTTC

**Supplementary Table S2**. Sequences of the 32 individual (77 to 79 nt-long) RNA aptamers selected after 10 rounds of SELEX process using PCBP-2 as the target molecule. Aptamers marked with an asterisk showed binding capacity to PCBP-2 higher than that of the last SELEX round population and M1-40 starting library (Figure 4) and were characterized by ELONA-RTqPCR (Figure 6 and Supplementary Figure S6). Nucleotides highlighted in bold correspond to the 40 nt-long selected sequence within each aptamer.

Name	RNA aptamer sequence
0.5RS10-02	GGGGCGGAUCCAGACUGGUGUCAUAUGAUUGUGUUUAGCGGGAGUACCUUGAUGUUUUGCGGCCCUAAAGACAAGCUUC
05RS10-03	GGGGCGGAUCCAGACUGGUGU <b>CUUGUCUAGGCCGGUAAGAUUGGAUGAUAAUUGUUUGG</b> GCCCCUAAAGACAAGCUUC
05RS10-04*	GGGGCGGAUCCAGACUGGUGU <b>CAUUUAGCAAAAACACUUGUAUAAUUCAAGUCGAUGUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-05	GGGGCGGAUCCAGAGUGGUGU <b>GUUGUUAAACGGUGGAUUGGUUUAUUAGUGUUUAGGCG</b> GCCCUAAAGACAAGCUUC
05RS10-06	GGGGCGGAUCCAGACUGGUGU <b>CGCCUUUAGUGUACACAAUAUAUCCUUCCUCUGUUGGGCG</b> GCCCUAAAGACAAGCUUC
05RS10-07	GGGGCGGAUCCAGACUGGUGU <b>CGGGAACUAUCGGCUUGCGACUAUUUACCUGUGUCAUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-08	GGGGCGGAUCCAGACUGGUGU <b>CAUAUGAUUGUGUUUAGCGGGAGUACCUUGAUGUUUUGCG</b> GCCCUAAAGACAAGCUUC
05RS10-09*	GGGGCGGAUCCAGACUGGUGUACACGGUGUUUAGUAGUUUAAUGAAUCUUUUAGUUCUUGGGCCCUAAAGACAAGCUUC
05RS10-10	GGGGCGGAUCCAGACUGGUGU <b>UACCAUUAGCCGACGCCCUCUCUCACUUAUGUGUCGCUGG</b> GCCCUAAAGACAAGCUUC
05RS10-11*	GGGGCGGAUCCAGACUGGUGU <b>GAUCAUAUUAAUAAGACGCUUCCAGGUACGUCGCUGUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-12	GGGGCGGAUCCAGACUGGUGU <b>UCCUCUGACACUUUCAAAACAUUGGCGUACUUCAUUCGUG</b> GCCCUAAAGACAAGCUUC
05RS10-13	GGGGCGGAUCCAGACUGGUGU <b>AUUUGGUAGGGCGUAUUAUUUUAAGAAUUUUGUUGCGUGG</b> GCCCUAAAGACAAGCUUC
05RS10-14	GGGGCGGAUCCAGACUGGUGU <b>CAUUAAAAAACUAAUCUAUUUCUGGUCGUGUAUAGUCUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-15	GGGGCGGAUCCAGACUGGUGU <b>UUUGUUCUAUCGGGUUUCUCAAUGUGUUGUUGUCAGUGG</b> GCCCUAAAGACAAGCUUC
05RS10-16	GGGGCGGAUCCAGACUGGUGU <b>GUUAAUUAAAAAACUUUGGUUCCCAUUUUCUCUCUUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-17	GGGGCGGAUCCAGACUGGUGU <b>UGCGUAAUUUGUGUUUUGAUAUAAGUGUACUCCUCACGCG</b> GCCCUAAAGACAAGCUUC
05RS10-18*	GGGGCGGAUCCAGACUGGUGU <b>UUAAUUAUGUAAGUAAAUUGUUUUUUGACUCUCGCAUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-19*	GGGGCGGAUCCAGACUGGUGU <b>AAUCGAUCUUGCAUGCUAUUCGUCAAUCAACUCUUGCCGG</b> CCCUAAAGACAAGCUUC
05RS10-20	GGGGCGGAUCCAGACUGGUGU <b>UUCCCUAGGACUUCCGACUAGUAAUGUUUGGUUUCCCGUG</b> GCCCUAAAGACAAGCUUC
05RS10-22	GGGGCGGAUCCAGACUGGUGU <b>ACUUCUAAAAACUUCUCCAGCAGGGAAACUUCGUUCCUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-23	GGGGCGGAUCCAGACUGGUGU <b>UCUUUUAAUAUAUAGGUCUUUUAUUAGUGUGUCUUUGUG</b> GCCCUAAAGACAAGCUUC
05RS10-24	GGGGCGGAUCCAGACUGGUGU <b>UCUAACGUCCUAUACUCAAUGGGUAUGCUUGUUUUAUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-25	GGGGCGGAUCCAGACUGGUGU <b>UUCCUAUCUUACCCGAGGUAUAACGUUUGAUUCGCGUGG</b> GCCCUAAAGACAAGCUUC
05RS10-26	GGGGCGGAUCCAGACUGGUGU <b>CUUUCUGUCCAGCUCUUAGGUUCAUCUUCAGGUCUACUGG</b> GCCCUAAAGACAAGCUUC
05RS10-27	GGGGCGGAUCCAGACUGGUGU <b>GUGUAUACACUCUGCAUUUUUAUUUGGACACUCAUGG</b> GCCCUAAAGACAAGCUUC
05RS10-28	GGGGCGGAUCCAGACUGGUGU <b>CGAAUAUUAUGAGUGUGUGCCGCAUGUCUUUCCUCGCUCG</b>
05RS10-29	GGGGCGGAUCCAGACUGGUGU <b>CGUUAUUUAACUUGAUAUUUUGAUCAUCGUCACGUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-30*	GGGGCGGAUCCAGACUGGUGU <b>UUCCGCAAAGAGUGGUCUUUGUUAAUGUCAGGUUUCUUCG</b> GCCCUAAAGACAAGCUUC
05RS10-31	GGGGCGGAUCCAGACUGGUGU <b>UUAAUCCUUACGUCCUUUUGCGGUUUUCGUGUGUUCUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-32*	GGGGCGGAUCCAGACUGGUGU <b>CUUCCUGCUUGUGUUAUUUUCUAUUGUCGUGCGUGUUCGG</b> GCCCUAAAGACAAGCUUC
05RS10-33	GGGGCGGAUCCAGACUGGUGU <b>GUAGGUGACUUGGUUAUCCUGUUUCACUAACUUUACUUGG</b> GCCCUAAAGACAAGCUUC
05RS10-34*	GGGGCGGAUCCAGACUGGUGUGAACACAGACGAGAACGUUGCAUAAAACCGCUUUUUUUGGGCCCUAAAGACAAGCUUC

## SUPPLEMENTARY FIGURES



С



**Supplementary Figure S1.** Configuration of ELONA-(RT)qPCR experiments performed in high capacity 96-well plates for the affinity analysis (**A**) and the quantification of *Kd* and *Bmax* (**B**) of DNA and RNA aptamers. The schematic representation of aptamer–PCBP-2 binding in the ELONA format corresponding to panel **B** is shown in panel **C**.



**Supplementary Figure S2.** Nucleotide composition of the 10th round of RNA (blue bars) and DNA (red bars) aptamers selection against PCBP-2.



**Supplementary Figure S3.** Quality control of the amplification products resulting from either qPCR of the template molecule D-ACTG (**A**) or RTqPCR of the template molecule R-ACUG (**B**). The DNA products resulting from (RT)qPCR amplification using the upper template concentrations shown in Figure 2 were loaded in a non-denaturing 10.0% (19:1) acrylamide/bis-acrylamide gel electrophoresis (in 0.5 X TBE), which was run at 100 V for 1 hour. MW: Molecular weight DNA marker (50 pb).



**Supplementary Figure S4.** Calibration curves obtained using four high affinity DNA (**A**) and RNA (**B**) aptamer molecules as templates for (RT)qPCR amplification, with SYBR Green as fluorophore. Consensus calibration curves for each group of four curves are shown in black, and the curves corresponding to D-ACTG and R-ACUG templates (in red, already depicted in Figure 2) are superimposed in the interval of six orders of magnitude assayed.



**Supplementary Figure S5.** Minimum free energy (MFE) structure drawings (predicted by mfold software using the ionic conditions of the SB and a folding temperature of 37°C) of the eight high-affinity ssDNA aptamers specific to PCBP-2 whose functional analysis is shown in Figure 5. The free energies of the MFE depicted are: 05DS10-01, -5.31 kcal/mol; 05DS10-02, -4.74 kcal/mol; 05DS10-05, -1.35 kcal/mol; 05DS10-12, -3.18 kcal/mol; 05DS10-18, -2.84 kcal/mol; 05DS10-21, -2.46 kcal/mol; 05DS10-22, -2.13 kcal/mol; 05DS10-26, -1.75 kcal/mol.



**Supplementary Figure S6.** Minimum free energy (MFE) structure drawings (predicted by RNAfold software) encoding base-pair probabilities of the eight high-affinity RNA aptamers specific to PCBP-2 whose functional analysis is shown in Figure 6. The free energies of the MFE depicted are: 05RS10-04, -15.10 kcal/mol; 05RS10-09, -14.10 kcal/mol; 05RS10-11, -16.50 kcal/mol; 05RS10-18, -10.80 kcal/mol; 05RS10-19, -15.10 kcal/mol; 05RS10-30, -23.40 kcal/mol; 05RS10-32 -16.60 kcal/mol; 05RS10-34, -17.40 kcal/mol.



**Supplementary Figure S7.** Characterization of high affinity ssDNA individual aptamers present in the last SELEX round, by means of colorimetric ELONA. The affinity curves obtained for the eight selected individual aptamers (**A**) showed that the best fit curve corresponded to a *One site - specific binding* model (with R<sup>2</sup> values in the range 0.93-0.99) in all cases, from which the *Kd* and *Bmax* values were derived (**B**). In parallel, D-ACTG molecule used as a negative control (see text for details) could only be adjusted to a linear regression model, thus showing non-specific binding to PCBP-2.



**Supplementary Figure S8.** Full-length EMSA gels showing the aptamer–PCBP-2 complexes formed by two high affinity RNA aptamers: 05RS10-09(A, C) and 05RS10-32(B, D). Short (16h: A, B) and long (80h: C, D) exposure times at  $-80^{\circ}$  C were used in both cases. Boxes in panels C and D correspond to panels A and B of Figure 7.